Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198951 | 0.83 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL14696607 | 0.81 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL21199074 | 0.79 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL174157 | 0.78 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL16896797 | 0.78 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL9810683 | 0.78 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL27343291 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL27629656 | 0.78 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL27747903 | 0.78 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1PKMTAAR1HIF1A | |
| SCHEMBL15544605 | 0.77 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1PKMTAAR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | L3MBTL1 3406/4885ALDH1A1 855/4885PKM 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.